Alterations in mRNA and protein expression in human peripheral mononuclear blood cells (pmc) of schizophrenia patients treated with fluvoxamine augmentation of antipsychotics: Relationship to clinical symptoms and cognitive function
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Nov 2015
At a glance
- Drugs Fluvoxamine (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- 18 Feb 2009 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 14 Apr 2008 New trial record.